| M | T | W | T | F | S | S | |
|---|---|---|---|---|---|---|---|
 | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| 15 | 16 | 17 | 18 | 19 | 20 | 21 |
| 22 | 23 | 24 | 25 | 26 | 27 | 28 |
| 29 | 30 | 31 |
PHARMAXIS LTD (PXS)
Stock Code: PXS
Listing Date: 2003-11-10 00:00:00
Website: http://www.pharmaxis.com.au/
Industry: Pharmaceuticals, Biotechnology & Life Sciences
Principal Activities:
The company is a specialist pharmaceutical company committed to the research, development and commercialisation of human therapeutic products for chronic respiratory and autoimmune diseases and the development of an improved lung function test.
Address:
10 Rodborough Road, Unit 2
FRENCHS FOREST
NSW 2086
Phone: (02) 9454 7200
Fax: (02) 9451 3622
Executives & Directors
Mr Denis Hanley, Independent Director, Chairman
Dr Alan Robertson, Director, CEO
Dr John Villiger, Director
Mr Will Delaat, Director
Mr Malcolm McComas, Independent Director
Mr Peter Farrell, Independent Director
Mr David McGarvey, CFO
Company Podcasts
Subscribe to current and future audio events for this company by clicking on the podcast icon:
Company ASX Announcements
Company ASX announcements can be viewed on the ASX website.
Announcements from the preceding six months are shown below.
Click here to view this company's details on the ASX site
Company Events
| Annual General Meeting | Thu, 23 Oct 2008 02:30PM |
|
| Full Year Results | Wed, 13 Aug 2008 | |
| Interim Results | Mon, 11 Feb 2008 | |
| Annual General Meeting | Mon, 5 Nov 2007 02:30PM |
|
| Full Year Results | Fri, 10 Aug 2007 | |
| Interim Results | Thu, 8 Feb 2007 | |
| Annual General Meeting | Thu, 26 Oct 2006 12:00PM |
|
| Full Year Results | Tue, 8 Aug 2006 | |
| Interim Results | Fri, 10 Feb 2006 | |
| Annual General Meeting | Tue, 15 Nov 2005 02:30PM |
PHARMAXIS LTD (PXS)
| Appendix 3B - Option Issue | Fri, 24 Oct 2008 |
| Change of Director`s Interest Notice - Options | Fri, 24 Oct 2008 |
| Appendix 3B - Option Grants to Employees | Fri, 24 Oct 2008 |
| AGM Outcome of Resolutions | Fri, 24 Oct 2008 |
| CEO Presentation to 2008 AGM | Thu, 23 Oct 2008 |
| Chairman`s Address to AGM | Thu, 23 Oct 2008 |
| Pharmaxis Aridol Approved for Sale in Switzerland | Mon, 20 Oct 2008 |
| Quarterly Report to Shareholders September 2008 | Wed, 15 Oct 2008 |
| Appendix 4C - Quarterly Cash Flow | Wed, 15 Oct 2008 |
| Quarterly Report to Shareholders and Investor ConferenceCall | Mon, 13 Oct 2008 |
| Pharmaxis Research Programs Highlighted at ERS | Fri, 3 Oct 2008 |
| Pharmaxis Files Aust Marketing Application for Bronchitol | Wed, 1 Oct 2008 |
| US SEC Filing of Annual Report on Form 20 F | Tue, 16 Sep 2008 |
| 2008 Statutory Annual Report | Tue, 16 Sep 2008 |
| 2008 Annual Review | Tue, 16 Sep 2008 |
| Notice of 2008 Annual General Meeting/Proxy Form | Tue, 16 Sep 2008 |
| Second Pivotal Phase 3 Trial in Cystic Fibrosis Begins | Thu, 4 Sep 2008 |
| Investor Presentation - Update | Mon, 1 Sep 2008 |
| Change of Director`s Interest Notice | Wed, 27 Aug 2008 |
| 12 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectas | Wed, 20 Aug 2008 |
| Bronchitol Phase 3 Cystic Fibrosis Trial Closes Recruitment | Mon, 18 Aug 2008 |
| Preliminary Final Report | Wed, 13 Aug 2008 |
| Proposed Issue of Options to Executive Director | Tue, 12 Aug 2008 |
| Appendix 3B Option Issue | Tue, 12 Aug 2008 |
| Bronchitol Cystic Fibrosis Dose Trial Results Positive | Tue, 12 Aug 2008 |
| Exercise of Employee Options | Thu, 7 Aug 2008 |
| Quarterly Report to Shareholders - June 2008 | Wed, 23 Jul 2008 |
| Appendix 4C - quarterly | Wed, 23 Jul 2008 |
| Quarterly Report and Investor Conference Call Timing | Mon, 21 Jul 2008 |
| Issue of options to recently appointed employees | Mon, 30 Jun 2008 |
| Proposed Issue of Options | Tue, 24 Jun 2008 |
| Initial Director`s Interest Notice | Tue, 24 Jun 2008 |
| New Pharmaxis Board Appointment | Tue, 24 Jun 2008 |
| Pharmaxis Concludes Special Protocol Assessment with FDA | Fri, 20 Jun 2008 |
| Pharmaxis Establishes Named Patient Program for Bronchitol | Tue, 17 Jun 2008 |
| Long-term safety study of Bronchitol completes | Thu, 12 Jun 2008 |
| Change in substantial holding | Tue, 27 May 2008 |
| Pharmaxis` Aridol Authorised for Sale in Germany | Mon, 19 May 2008 |
| Regulatory Path for Bronchitol in Bronciectasis | Thu, 1 May 2008 |
| Issue of employee options | Wed, 23 Apr 2008 |
| Change in substantial holding | Tue, 22 Apr 2008 |
| Ceasing to be a substantial holder | Fri, 18 Apr 2008 |
| Appendix 4C - quarterly | Tue, 15 Apr 2008 |
| March 2008 Quarterly Report to Shareholders | Tue, 15 Apr 2008 |
| Change in substantial holding | Mon, 14 Apr 2008 |
| Quarterly Investor Conference Call Details | Fri, 11 Apr 2008 |
| Cystic Fibrosis Trial in Children Returns Positive Data | Fri, 4 Apr 2008 |
| Change in substantial holding | Thu, 3 Apr 2008 |
| Becoming a substantial holder | Wed, 2 Apr 2008 |
| Ceasing to be a substantial holder | Wed, 2 Apr 2008 |
Please note: This company appears on this website as a result of its listing on the Australian Securities Exchange. Boardroom Radio does not claim any association with any company listed on this site.